ResMed to Lead or Sponsor 15 Studies at SLEEP 2019
Research advances best practices in the screening, diagnosis, and treatment of sleep apnea

SAN ANTONIO, June 6, 2019 – ResMed (NYSE: RMD, ASX: RMD) will showcase its medical research leadership at the upcoming SLEEP 2019 conference, presenting and/or sponsoring 15 abstracts that together highlight the updated prevalence of sleep apnea and best practices for diagnosing and effectively treating this common chronic disease.

The abstracts will be presented at the Henry B. González Convention Center, 900 E. Market Street. They include (all presentation times U.S. Central):

Sunday, June 9, 5:15 p.m.

Americas Prevalence of Obstructive Sleep Apnea (OSA) in Adults: Estimation Using Currently Available Data


  • Data based on analysis of ResMed’s 2018 “Global Prevalence of OSA” study, finding more than 936 million people worldwide are living with sleep apnea, nearly 10 times greater than previous estimates.

Monday, June 10, 5:15 p.m.

Improvements in Quality of Life in Female OSA Patients Using a Gender-specific Auto-adjusting Positive Airway Pressure Device

Patients Who Immediately Struggle with CPAP: Identifying a Patient Population in Need of Early Intervention

User Satisfaction with New Foam Cushion Full Face Mask

Tuesday, June 11, 1:45 p.m.

Effect of CPAP Use on Readmission Rates in Hospitalized Patients with Cardiovascular Disease and Sleep-disordered Breathing

Association of Positive Airway Pressure Use with Acute Care Utilization and Costs

Wednesday, June 12, 1:45 p.m.

Risk Factors for Positive Airway Pressure Adherence in Children with Sleep Apnea: Results Derived Using a Big Data Approach

For details and exact locations of presentations, visit ResMed’s Booth #617.

For interview requests, email Jayme Rubenstein at

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit and follow @ResMed.


MEDIA: Jayme Rubenstein, 858.836.6798, | INVESTORS: Amy Wakeham, 858.836.5000,
Media contacts - Bottom Blue - All Interior Pages

Media contact

Jayme Rubenstein
(858) 836-6798


Receive ResMed news releases when they publish.


ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages